Potential Mutagenic Impurity (GTI) Assessments
Impurities in drug substances and drug products typically arise from synthesis and/or are degradants. However, some impurities, which are highly reactive because of their structure, have the potential to interact with DNA.
A mutagenicity assessment must be performed for all confirmed impurity/degradant structures found during the scientific evaluation of investigational drug substances and products in order to comply with ICH M7 guidance. Arcinova has the capability to arrange these assessments using a range of different software tools.
Bio2Business 2018Bio2Business Basel 2018 will be attended by Nathalie Huther, Business Development Manager Europe.
Bio2Business 2018Dates: 19th - 20th JuneLocation: Basel, Switzerland
ChemSpec EuropeThe ChemSpec Europe Conference will be attended by Gareth Jenkins, Chief Scientific Officer at Arcinova. Gareth has been invited to chair 'Sessions 3 and 5' for the Royal Society of Chemistry's Special Symposium, during the two-day event.
ChemSpec EuropeDates: 20th - 21st June 2018Location: Cologne, Germany
Scale-up of Chemical Processes ConferenceThe Scale-up of Chemical Processes Conference will be attended by Nathalie Huther, Business Development Manager Europe.
Scale-up of Chemical Processes ConferenceDates: 25th - 27th JuneLocation: Prague